Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.
Janssen, R A
Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients. [electronic resource] - British journal of cancer Sep 1995 - 795-9 p. digital
Publication Type: Clinical Trial; Journal Article
0007-0920
10.1038/bjc.1995.414 doi
Adjuvants, Immunologic--metabolism
Antibodies, Bispecific--metabolism
Antigens, Neoplasm--pharmacology
Carcinoma, Renal Cell--immunology
Cell Adhesion Molecules--pharmacology
Epithelial Cell Adhesion Molecule
Humans
Immunoglobulin Fragments--metabolism
Immunotherapy, Active
Injections, Intravenous
Interleukin-2--therapeutic use
Kidney Neoplasms--immunology
Leukopenia--chemically induced
Lymphocyte Activation--drug effects
T-Lymphocytes--immunology
Tumor Necrosis Factor-alpha--metabolism
Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients. [electronic resource] - British journal of cancer Sep 1995 - 795-9 p. digital
Publication Type: Clinical Trial; Journal Article
0007-0920
10.1038/bjc.1995.414 doi
Adjuvants, Immunologic--metabolism
Antibodies, Bispecific--metabolism
Antigens, Neoplasm--pharmacology
Carcinoma, Renal Cell--immunology
Cell Adhesion Molecules--pharmacology
Epithelial Cell Adhesion Molecule
Humans
Immunoglobulin Fragments--metabolism
Immunotherapy, Active
Injections, Intravenous
Interleukin-2--therapeutic use
Kidney Neoplasms--immunology
Leukopenia--chemically induced
Lymphocyte Activation--drug effects
T-Lymphocytes--immunology
Tumor Necrosis Factor-alpha--metabolism